{"id":"W2249012585","doi":"10.1200/jco.2007.25.18_suppl.8003","title":"Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom’s macroglobulinemia at well-tolerated doses","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Tolerability; Macroglobulinemia; Multiple myeloma; Proteasome inhibitor; Internal medicine; Waldenstrom macroglobulinemia; Oncology; Progressive disease; Dosing; Adverse effect; Gastroenterology; Pharmacology; Lymphoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001117901,0.001298983,0.001167612,0.0004774453,0.0003954123,0.0005558112,0.0007826952,0.001098294,0.002372966],"category_scores_gemma":[0.0004335257,0.0004491505,0.0006771874,0.0003442696,0.0006301089,0.0004422469,0.0002694514,0.002051079,0.000596741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008284166,"about_ca_system_score_gemma":0.001168367,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001004055,"about_ca_topic_score_gemma":0.001808963,"domain_scores_codex":[0.9997194,0.0001062089,0.00001459749,0.00003845816,0.00004090884,0.00008046265],"domain_scores_gemma":[0.9996899,0.00004385008,0.0000613326,0.00002561756,0.00003017237,0.0001491212],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3491335,0.1187193,0.008548023,0.001285611,0.0008697103,0.0006935059,0.0006469767,0.005640218,0.3394718,0.0006558415,0.007352299,0.1669832],"study_design_scores_gemma":[0.2255293,0.7061328,0.02375073,0.00004339811,0.0004121879,0.000751139,0.00007139782,0.001734012,0.03577739,0.0001774007,0.005586417,0.00003395838],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936697,0.001648962,0.0005145082,0.0002581023,0.0000465166,0.00186352,0.0005487867,0.0001065817,0.001343391],"genre_scores_gemma":[0.9913663,0.001346107,0.001281857,0.0003211202,0.00009006061,0.001911778,0.001757715,0.00002495073,0.001900079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002372966,"threshold_uncertainty_score":0.007938385,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2234053623912945,"score_gpt":0.5196783874375903,"score_spread":0.2962730250462958,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}